Pritzker School of Medicine, University of Chicago, Chicago, Illinois, U.S.A..
Pritzker School of Medicine, University of Chicago, Chicago, Illinois, U.S.A.
Arthroscopy. 2021 Apr;37(4):1110-1114.e5. doi: 10.1016/j.arthro.2020.11.046. Epub 2020 Dec 2.
We sought to clarify the relationship between chronic preoperative opioids and complications following rotator cuff repair. Specifically, we assessed revision, a definitive postoperative end point for surgical outcome.
This study used PearlDiver, a United States national insurance claims database. All patients undergoing rotator cuff repair from 2008 to 2018 were identified and stratified based on a minimum of 2 opioid prescriptions within the 6 months before surgery, with 1 prescription occurring within 0 to 3 months before surgery and a second prescription within 4 to 6 months before surgery. Univariate logistic regressions of risk factors were conducted, followed by multivariate analysis of comorbidities, including ongoing preoperative opioids, any preoperative nonsteroidal anti-inflammatory drug (NSAID) prescriptions, age, sex, diabetes, tobacco, and obesity.
In total, 28,939 patients undergoing rotator cuff repair were identified, of whom 10,695 had opioid prescriptions within both 0 to 3 months and 4 to 6 months before index rotator cuff repair, whereas 18,244 had no opioid prescriptions within the 6-month preoperative period. In total, 977 (3.4%) patients underwent revision within 6 months, which increased to 1311 (4.5%) within 1 year of the index procedure. In the multivariate analysis controlling for age, preoperative NSAID prescriptions, tobacco, diabetes, obesity, and sex, we observed a significant association between chronic preoperative opioid prescriptions and rotator cuff repair revision (6-month odds ratio 1.12; P = .021, 1-year odds ratio 1.43; P < .001) following index procedure.
We report increased rates of revision within both 6 months and 1 year in patients with prolonged preoperative opioid prescriptions. The opioid cohort had greater rates of preoperative NSAID use and tobacco use, which also were observed to be independent risk factors for revision at both timepoints.
III; Retrospective comparative study.
我们旨在阐明慢性术前阿片类药物与肩袖修复术后并发症之间的关系。具体而言,我们评估了翻修术,这是手术结果的明确术后终点。
本研究使用了 PearlDiver,这是一个美国国家保险索赔数据库。从 2008 年到 2018 年,所有接受肩袖修复的患者都被确定,并根据术前 6 个月内至少 2 次阿片类药物处方进行分层,其中 1 次处方发生在术前 0 至 3 个月内,第 2 次处方发生在术前 4 至 6 个月内。进行了风险因素的单变量逻辑回归,然后对合并症进行了多变量分析,包括术前持续使用阿片类药物、任何术前非甾体抗炎药(NSAID)处方、年龄、性别、糖尿病、吸烟和肥胖。
共确定了 28939 例接受肩袖修复的患者,其中 10695 例在索引肩袖修复前 0 至 3 个月和 4 至 6 个月内有阿片类药物处方,而 18244 例在术前 6 个月内没有阿片类药物处方。共有 977(3.4%)例患者在 6 个月内接受了翻修术,在索引手术后 1 年内增加到 1311(4.5%)例。在多变量分析中,控制年龄、术前 NSAID 处方、吸烟、糖尿病、肥胖和性别,我们观察到慢性术前阿片类药物处方与肩袖修复翻修之间存在显著关联(6 个月时的优势比 1.12;P =.021,1 年时的优势比 1.43;P <.001)。
我们报告称,在术前阿片类药物处方时间延长的患者中,6 个月和 1 年内翻修的发生率均增加。阿片类药物组术前 NSAID 使用率和吸烟率更高,这两个因素在两个时间点也被观察到是翻修的独立危险因素。
III;回顾性比较研究。